AstraZeneca Pharma India Ltd. — Interim / Quarterly Report 2022

Aug 9, 2021

AstraZeneca4

==> picture [102 x 95] intentionally omitted <==

----- Start of picture text -----

81'1n11ing scltn.ce to pa,tlenb: since 1979
4a
----- End of picture text -----

August 9, 2021

The Manager - Listing

BSE Limited, 1 [st ] Floor, New Trading Ring Rotunda Buiding, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager - Listing

National Stock Exchange of India Ltd.

Exchange plaza, 5[th ] Floor, Plot No.C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 40005 I

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Monday, August 91 2021 Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

The Board of Directors of the Company at their meeting held today i.e, August 9, 2021, has inter-alia:

1. Approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2021. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 9, 2021 are enclosed herewith.

2. Declared Interim Dividend of Rs. 2 per equity share for the financial year 2021-22

3. Fixed August 20, 2021 as the Record Date for determining the entitlement of the shareholders for the payment of aforesaid Interim Dividend

This is for your kind information and records.

Thanking you,

For AstraZeneca Pharma India 1,;11· ltl�N>

Prat ra Compan Secretary & Legal

TEL : +91 BO 6774 8000 FAX : +91 80 6774 8857 CIN : L24231KA1979PLC003563 WEB : www.astrazeneca.com/india

FACTORY TEL : +91 80 6774 9000 12th Mile on Bellary Road Venkatala, Kattigenahalli Village Yelahanka FAX : +91 80 2846 2208 Bangalore - 560 063 +91 80 6774 9628 INDIA

CORPORATE & REGO. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N 1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA

AslraZ.,.,eca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyala Embassy Buaineaa Park, Rachenahalll, Outer Ring Road, Bangalore 580 045 Statement or unaudited financial nisulta for the quarter ended 30 June 2021

	'R Inlo •i<e1t for um lncs par share data	'R Inlo •i<e1t for um lncs par share data	'R Inlo •i<e1t for um lncs par share data	'R Inlo •i<e1t for um lncs par share data
SI No.	Parular 3 months ended 30/062 0 21 Unauitd	Previous 3 mnth& Corolng 3 end 31/3/2021 mnt& anded In th prev yer 3 0 Refernote6 Unauited		Year ondnd 31/03/202 Audited
1 2 3 � 5 8 1 8 9 10 11 12 13 � Revenue a) Re. ro otins 17.54.2 21,025 71 b) 0 ice 28.9 22 Total Incom 17,830.18 21.280.97 . Epnss (al Costofmaials csu 1,787.9 2,62,8 (b) Purcs of s-ir 3.305.6 5,69.47 (c)Changu in inwnloilofnis gs, wrk-in-porss ed 1,572.9 !69,52) slo-1n-e (d)Em�oy bs eJnse 5,479.3 S249.& (e)D o ad in nt Bx 476,08 5.19 (fAllown f e ct lo (nt) 12925 81.47 19) Selling mig a dilio epense 1,028 45 1,015.14 (h) Ot ense 2.692 2,9 6 (I) Fina cst 25 2.18 Totel•,- 18,479.78 17,517.11 Prft befor exceptol ond extr.nMr !lam and tax (1•2) 1,30.4 3,Sl.16 Exll its - Prnt. extonry lle an tu (3+4) 1, 350.4 38186 En al . Pnt bfre we l�&) 130.40 3,683.8 6 Tuunn -Coentt 41665 85.87 • Dam t (90.5) 101,10 Totl t upen 328.07 9517 Prt af or !al 17 -) 1,024 .3 3 2,72 7.81 Other comrtln1mlw inomeoas) A Ite• lht Wlil n b rcasalfetopofl or loss R&easuremet (ns(loses) o posemlytbneft c\l (12.32) 39.25 In ta e o ave 310 (9 il Total othe coh iYl Inom (109), net of lncnme tx (9.2�) 276.J2 Total coehnive lnc: fr t pro (110) 1015.11 3,0021 Pia-p a� , cpit 600 .00 5. (FQt '&IU ol Rs 2-p oit sh) R<u (ex 1aluo rrves a p balan sh t) 0 Emlngs pr aqulty sh of Rs 2- nch (baolc and dluted) 4.10 10.1			19.357 76 81,35.3 2.8 128414 19,6225 8 2,60 5 2 2,085.3 9,725.78 4,711.22 19,474.2 459,18 294.59 564.75 21,95.l 416 2,012 59 (178) 271.9 93.8 4,520.88 2,70.10 11,57.89 27.39 103 16984.12 89,931.14 2,638.44 12,709.38 263.4 12709.36 2,838.44 12,709.38 859.5 3,48.78 (a5) (10.75) 7417 3,379.03 1,8.47 9,330.35 98.16 457.98 (24 71) (115.2) 73.4 8 342.70 1,t3693 9,673.0$ 5 . 00 50.0 - 45,117.28 7.46 3732

==> picture [38 x 79] intentionally omitted <==

==> picture [108 x 59] intentionally omitted <==

AstraZeneca Pharma India Limited

Regd. Office: Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited flnanclal results for the quarter ended 30 June 2021

Notes:

• The financial results have be n prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Ad, 2013 and other recognised accounting practices and policies to the extent applicable.

• 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has be n provided.

• 3 The Company, which is in the business of manufacture and supply of essential goods, has been assessing the impact of the COVID-19 pandemic (including the second wa11e) on its busines and beli81/es that lhe pandemic does not have a material impact oo the current or Mure operations, financial position and liquidity of the Company Management has considered all significant possible impact of known events arising from the pandemic in the preparation of these financial results. Assessing the impact of COVID-19 is, however, a continuing process given the uncertainties associated with its nature and duration. The Company will continue to closely monitor any material changes to future economic conditions.

• 4 During the quarter, the Company received a demand notice for an amount of Rs.15, 738.9 lakhs (and inter st thereupon) under Trade Margin Rationalisation notification {"TMR notification") from National Phannaceutical Pricing Authority (NPPA) alleging overcharging of a patented anti-cancer drug sold during the period of 8 March 2019 to 31 January 2021 The said drug has been included with certain other anti-cancer medicines. on which trade margin caps are applicable under TMR notification. Based on evaluation, Management is of the View that the TMR notification is not applicable to the aforesaid patented drug and all applicable laws relating to the pricing of the product have been complied with. The Company has filed a Writ Peti on before the High Court of Delhi challenging the NPPA's demand notice. Base<I on asses ment. supported by external legal advice, Management has conctuded that it has a strong case and the Company can defend its position. Accordingly, no proVision has been made in these financial results.

• 5 The Board of Directors, at its meeting dated 09 August 2021, has declared an interim dMdend of Rs. 21- per equity share aggregating to Rs 500.0/- lakhs

• 6 The iigures for the quarter ended 31 March 2021 are the balancing figures between the audited figures in respect of the lull financial year 31 March 2021 and the publ shed unaudited year to date figures up to the third quarter of the respective financial year i.e., 31 December 2020 which were subjected to review by the statutory auditors.

• 7 · Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's p,esentatioo for the purpose of comparability.

• 8 This statement of finanacial results was reviewed and recommended by the AUdit Commiltee of the Board and subseq enHy approved by the Board of Directors at their respective meetings held on 09 August 2021. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 June 2021.

==> picture [74 x 41] intentionally omitted <==

----- Start of picture text -----

)
Place: Bengaluru
Oats: 09 August, 2021
----- End of picture text -----

==> picture [108 x 60] intentionally omitted <==

==> picture [130 x 116] intentionally omitted <==

----- Start of picture text -----

By Order of the B011rd of Directors
For Ast eneca Pharma India Limited
�
,. [' ]
Gaga I g Bedi
Mana Ir r
----- End of picture text -----

Price Waterhouse & Co Chartered Accountants LLP

Independent Auditors' Review Report on the Statement of Unaudited Financial Results

To The Board of Directors AstraZeneca Pharma India Limited Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bengaluru - 560 045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended June 30, 2021 which are included in the accompanying 'Statement of unaudited financial results for the quarter ended June 30, 2021" and the notes thereon (together referred to as the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP Firm Registration Number: 304026£/ E-300009 D ,i�.�.� Partner J�Qg Membership Number: 206477 UDIN: 21206477AAAAAY8916

Place: Bengaluru Membership Number: 206477 Date: August 09, 2021 UDIN: 21206477AAAAAY8916 ... , ... ,. ·-�················· -........ -... , .......................... ,.·-··�··············· ..................................................... , ..... ' ... ..................................................[.] ..... , .[.] ...[......] .. .[.]

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road Wsoor, Bangalore-560 008

T:+91 (Bo) 4079 5000, F:+91 (Bo) 4079 5222

Registered office and Head office: Plot No. Y -14. Block EP, Sector V, Sall Lake Electronic Complex, Bidhan Nagar. Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Llablllty Partnership with LLP Identity no: LLPIN AA�362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E-300009 (ICAI registration number before conversion was 304026E)